Alphamab Oncology
9966 · HKEX
Public Market Listing
Live quotes, historical charts, and market capitalization for Alphamab Oncology are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | HER2 (biparatopic — extracellular domains II and IV)Antibody–drug conjugate | Breast CancerColorectal Cancer HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer | |
| Phase 3 | PD-L1 + CTLA-4Multispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 2 | HER3 + TROP2Antibody–drug conjugate | Non-Small Cell Lung CancerBreast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 2 | HER2 (JSKN003 ADC component) + PD-L1 (envafolimab component)Combination | Non-Small Cell Lung Cancer |
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
December 2026 (2)
What to watch
2027 (5)
2028 (1)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $44M | $35M | $230M | — | report ↗ |
Alphamab Oncology reported total revenue of RMB 319.44 million for the six months ended June 30, 2025, up 84.05% YoY, with product revenue attributable to the Company of RMB 67.02 million. R&D expenditure reached RMB 253.16 million, up 30.14% YoY, and the company recorded a profit of RMB 21.58 million versus a loss of RMB 44.90 million in H1 2024, representing a year-on-year turnaround from loss to profit. Cash reserves stood at RMB 1,644.79 million as of June 30, 2025.
Business progress included KN026’s phase II/III trial meeting its primary endpoint in HER2-positive gastric cancer, with an NDA submission planned for that indication, and JSKN003 advancing multiple phase III trials in breast and ovarian cancer while receiving U.S. FDA orphan drug designation for gastric cancer. Envafolimab data were presented at ASCO, JSKN016 completed enrollment in HER2-negative breast cancer cohorts, and JSKN033 progressed through dose escalation. The company also outlined 2025 milestones including pivotal study filings for JSKN016 and JSKN003, and initiation of a phase I study for JSKN022.
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $193M | $16M | report ↗ |
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $89M | $56M | $215M | — | report ↗ |